Wolverine Trading’s PTC Therapeutics PTCT Stock Holding History

Wolverine Trading’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,836	Closed	-$564K	–	6056
2025 Q2	$540K	Buy	+10,836	New	+$514K	﹤0.01%	2877
2023 Q2	–	Sell	-4,909	Closed	-$240K	–	4793
2023 Q1	$240K	Buy	+4,909	New	+$224K	﹤0.01%	3247
2020 Q1	–	Sell	-14,367	Closed	-$723K	–	5132
2019 Q4	$683K	Sell	14,367 -3,298	-19%	-$140K	﹤0.01%	2778
2019 Q3	$612K	Buy	+17,665	New	+$769K	﹤0.01%	2423
2019 Q2	–	Sell	-23,151	Closed	-$914K	–	4989
2019 Q1	$871K	Buy	23,151 +13,498	+140%	+$453K	﹤0.01%	2214
2018 Q4	$309K	Buy	9,653 +68	+0.7%	+$2.44K	﹤0.01%	3148
2018 Q3	$450K	Buy	9,585 +1,070	+13%	+$44.3K	﹤0.01%	3229
2018 Q2	$230K	Hold	8,515	–	–	﹤0.01%	4183
2018 Q1	$230K	Sell	8,515 -10,112	-54%	-$256K	﹤0.01%	4183
2017 Q4	$311K	Buy	+18,627	New	+$315K	﹤0.01%	3580
2017 Q3	–	Sell	-14,017	Closed	-$274K	–	4883
2017 Q2	$259K	Buy	+14,017	New	+$189K	﹤0.01%	3253

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's PTCT Position: Q3 2025 in Review

Wolverine Trading sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 10,836 shares — an estimated $564K sold.

Wolverine Trading first reported a position in PTCT in Q2 2017 and held it in 11 quarters. The position peaked at $871K in Q1 2019. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

Wolverine Trading reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
Wolverine Trading sold 10,836 PTC Therapeutics shares in Q3 2025, an estimated $564K.
Wolverine Trading first reported a position in PTC Therapeutics in Q2 2017 and held it in 11 quarters.
Wolverine Trading's PTC Therapeutics position peaked at $871K in Q1 2019.
293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.